United States News Todas as matérias

Europe faces rising uncertainty as Trump’s Greenland ambitions test Nato unity and expose EU vulnerabilities.

China faces growing uncertainty in South America after Trump’s dramatic intervention in Venezuela reshaped regional power dynamics.

Pro-crypto Senator Cynthia Lummis criticises reported Bitcoin sales by the US government despite plans for a strategic reserve.

US carmakers report their best sales performance in years as Trump-era trade and industry policies defy earlier forecasts.

A new US bill seeks to bar politicians and federal staff from trading prediction market contracts tied to policy and politics.

Ascentage Pharma (NASDAQ:AAPG) shares were in focus on Tuesday, January 6, 2026, following the announcement that the U.S. FDA has cleared its Investigational New Drug (IND) application for APG-3288.

8x8 (NASDAQ:EGHT), a global leader in integrated cloud communications, announced on Tuesday, January 6, 2026, that it has acquired Maven Lab, a Singapore-based specialist in mobile marketing and enterprise messaging.

The acquisition is a strategic "step-change" for 8x8, designed to cement its leadership in the high-growth Asia-Pacific (APAC) customer engagement market.

By integrating Maven Lab’s team and its acclaimed Moobidesk platform into the 8x8 Platform for CX, the company is pivoting from traditional messaging toward "orchestrated, omnichannel customer journeys."

Moobidesk offers a unified interface for SMS, WhatsApp, Viber, LINE, and voice, featuring smart AI routing and automated response suggestions that have been shown to increase sales leads by an average of 10% for its enterprise clients.

The move comes as the CPaaS (Communications Platform as a Service) market is projected to grow from $32 billion today to nearly $100 billion by 2030.

With Maven Lab’s deep local carrier relationships and regional expertise, 8x8 is now uniquely positioned to support mission-critical, high-volume communications for the finance, healthcare, and logistics sectors across Southeast Asia.

HUTCHMED (China) Limited (NASDAQ:HCM) shares climbed in after-hours trading Wednesday after the company announced that its novel Syk inhibitor, sovleplenib, met the primary endpoint in the Phase III registration portion of the ESLIM-02 trial.

Baidu (NASDAQ:BIDU) announced on Wednesday, January 7, 2026, that its autonomous ride-hailing platform, Apollo Go, has received Dubai’s first-ever permit for fully driverless vehicle trials on public roads.

Caracas and Washington have agreed to send up to $2 billion worth of Venezuelan crude to U.S. refineries, a move that could reroute supply away from China.

Marvell Technology said on Tuesday it will buy networking equipment provider XConn Technologies in a deal worth ​about $540 million, as the chipmaker doubles down on data center hardware ‌amid a race to expand artificial intelligence infrastructure.

Ford Motor Company (NYSE:F) reported robust U.S. sales results for the fourth quarter and full year 2025, with Q4 sales rising 2.7% year-over-year and annual sales climbing 6% to approximately 2.2 million vehicles.

Johnson & Johnson (NYSE:JNJ) announced on Tuesday, January 6, 2026, that its Phase 2b JASMINE study of nipocalimab in adults with moderate-to-severe systemic lupus erythematosus (SLE) met its primary and key secondary endpoints.

Zai Lab Limited (NASDAQ:ZLAB) announced on January 6, 2026, that China’s National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for AUGTYRO™ (repotrectinib).

This approval targets adult patients with advanced or metastatic solid tumors harboring a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.

In a significant victory for food transparency advocates, a federal appeals court ruled on January 6, 2026, in favor of Natural Grocers (NASDAQ:NGVC), the Center for Food Safety, and a coalition of plaintiffs.

Abpro Holdings (NASDAQ:ABP) and South Korean biopharma giant Celltrion announced on January 6, 2026, that the U.S. FDA has cleared the Investigational New Drug (IND) application for ABP-102 (CT-P72).

This clearance transitions Abpro’s lead oncology program into the clinic, targeting a wide array of HER2-positive solid tumors, including breast, gastric, colorectal, and pancreatic cancers.

Alumis (NASDAQ:ALMS) surged as much as 82% in early trading Tuesday after its experimental oral drug, envudeucitinib, outperformed both a placebo and Amgen’s blockbuster Otezla in two Phase 3 trials for moderate-to-severe plaque psoriasis.

Genprex (NASDAQ:GNPX) announced landmark preliminary preclinical data on January 6, 2026, for its diabetes gene therapy candidate, GPX-002.

Cognition Therapeutics (NASDAQ:CGTX) announced on January 6, 2026, the publication of peer-reviewed results from its Phase 2 SHIMMER study in the journal Alzheimer's & Dementia.

Amgen (NASDAQ:AMGN) announced on January 6, 2026, the acquisition of Dark Blue Therapeutics, a UK-based biotech, for a total consideration of up to $840 million.

The deal centers on a first-in-class Targeted Protein Degrader (TPD) designed to treat specific, high-risk sub-populations of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL).

Actuate Therapeutics (NASDAQ:ACTU) reported successful Phase 1 results from its Actuate-1902 study on January 6, 2026.

The trial evaluated elraglusib, a first-in-class small molecule GSK-3β inhibitor, in 40 pediatric patients (ages 3–21) with relapsed or refractory solid tumors.

Edible Garden AG Incorporated (NASDAQ:EDBL) reported a 26.4% year-over-year increase in preliminary sales for the 2025 holiday period on January 6, 2026.

The gains were driven by robust demand for its core "Controlled Environment Agriculture" (CEA) products and a rapidly expanding retail footprint that now exceeds 5,000 locations across the U.S., Caribbean, and South America.

Atossa Therapeutics (NASDAQ:ATOS) reached a significant regulatory milestone on January 6, 2026, receiving a "Study May Proceed" letter from the U.S. FDA for its Investigational New Drug (IND) application.

Stereotaxis (NYSE:STXS), a global leader in endovascular surgical robotics, announced on Tuesday, January 6, 2026, that it has received U.S. Food and Drug Administration (FDA) approval for its MAGiC™ Magnetic Interventional Ablation Catheter.